Opportunities and Challenges of Safety Biomarker Qualification: Perspectives from the Predictive Safety Testing Consortium
FDA Works with Partners to Establish Important Therapeutic Area Data Standards Clarification, November 5, 2012: CFAST is a joint initiative of CDISC and the Critical Path Institute. The FDA and TransCelerate B
FDA, IMI, and Patient Advocates to Present at CDISC 2012 International Interchange Formal Launch of CFAST – Collaboration between C-Path and CDISC The Clinical Data Interchange Standards Consortium (CDISC) and Critical Path Institute (C-Path) announce the launch of the Coaliti
August 28, 2012 Towards Consensus Development: Qualifying Endpoint Measures for Rheumatoid Arthritis Clinical Trails August 28, 2012 Sheraton Silver Spring Hotel 8777 Georgia Avenue – Silver Spring, MD 20910 SPONSORED BY: Critical Path Insti
Approval of new drugs slowing Fewer new prescription drugs will get approved in the U.S. this year than the 30 approved in 2011, a ratings agency forecasts, add
CDISC, C-Path and FDA Collaborate to Develop Data Standards to Streamline Path to New Therapies The Clinical Data Interchange Standards Consortium (CDISC) and the Critical Path Institute (C-Path) announce the signing of a part
ACRO Testifies Before FDA on Clinical Trial Modernization WASHINGTON–(BUSINESS WIRE)– The Association of Clinical Research Organizations (ACRO) today provided the FDA with a nu
Future of medicine – the critical path forward I saw a presentation yesterday by Carolyn Compton, the new head of C-PATH, the critical path institute located in Tucson, AZ. This
House Energy and Commerce Committee Hearing C-Path’s work was positively acknowledged by Dr. Janet Woodcock during the April 18 House Energy and Commerce Committee Hear
